Deoxycholic Acid
Brand names: Kybella · Active ingredient: Deoxycholic Acid
In short: KYBELLA® is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. Limitations of U se KYBELLA is not approved for the treatment of subcutaneous fat outside the submental region, and such use is not recommended .
What is Deoxycholic Acid used for?
KYBELLA® is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.
Limitations of
U
se
KYBELLA is not approved for the treatment of subcutaneous fat outside the submental region, and such use is not recommended .
Deoxycholic Acid dosage
Before injection, see General Considerations for Administration
.
Inject KYBELLA into subcutaneous fat tissue in the submental area using an area-adjusted dose of 2 mg/cm2 (a single treatment of up to 100 mg (up to a total of 10 mL)) that consists of up to a maximum of 50 subcutaneous injections, (2 mg (0.2 mL)) each, spaced 1 cm apart.
Up to 6 treatments may be administered at intervals no less than 1 month apart.
KYBELLA should be administered by a healthcare provider.
Prior to KYBELLA treatment:
Screen patients for other potential causes of submental convexity/fullness (e.g., thyromegaly and cervical lymphadenopathy).
Consider the risks of KYBELLA use in patients with excessive skin laxity, prominent platysmal bands or other conditions for which reduction of submental fat may result in an aesthetically undesirable outcome.
Visually inspect KYBELLA vials for particulate matter and/or discoloration, and discard the vial if the solution is discolored and/or contains particulate matter (KYBELLA is clear, colorless and free of particulate matter).
Given that patients who have had prior surgical or aesthetic treatment of the submental area may have changes in anatomy/landmarks or scar tissue that may impact the ability of the health care provider to safely administer KYBELLA or to obtain the desired aesthetic result, use KYBELLA with caution in such patients.
The safe and effective use of KYBELLA depends on the use of the correct number and locations of subcutaneous injections, proper needle placement, and administration technique. Prior to administration, understand the relevant submental anatomy and associated neuromuscular structures in the area involved and any alterations to the anatomy due to prior surgical or aesthetic procedures .
Avoid Injections Near the Area of the Marginal Mandibular Nerve
To avoid injury to the marginal mandibular nerve:
Inject KYBELLA only within the target submental fat treatment area .
Do not inject above the inferior border of the mandible.
Do not inject within a region defined by a 1-1.5 cm line below the inferior border (from the angle of the mandible to the mentum).
Figure 1. Avoid the Marginal Mandibular Nerve Area
Avoid Injection into the Platysma
Prior to each treatment session, palpate the submental area to ensure sufficient
submental fat
and to identify subcutaneous fat between the dermis and platysma (pre-platysmal fat) within the target treatment area (Figure 2). The number of injections and the number of treatments should be tailored to the individual patient’s submental fat distribution and treatment goals.
Figure
2
. Sagittal View of Platy
s
ma Area
Administration Instructions
Consider use of ice/cold packs, topical and/or injectable local anesthesia (e.g., lidocaine) to enhance patient comfort. …
How to take Deoxycholic Acid — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Advise patients to contact their healthcare providers if they develop signs of marginal mandibular nerve paresis (e.g., asymmetric smile, facial muscle weakness) or difficulty swallowing, or if existing symptoms worsen .
Advise patients to contact their healthcare providers if they develop injection site hematoma, brusing, alopecia, ulceration, necrosis, nodule, mass, infection, pain, numbness, induration, or paresthesia from the treatment area .
Distributed by: AbbVie Inc.Manufactured for:AbbVie Inc.North Chicago, IL 60064
© 2026 AbbVie. All rights reserved.KYBELLA and its design are trademarks of Allergan Sales, LLC, an AbbVie company.
Patented. See www.abbvie.com/patents
V5.0USPI0101
Warnings & precautions
Do not take this medicine if: KYBELLA is contraindicated in patients with an infection in the injection area.
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness (paresis), were reported in KYBELLA-treated patients during clinical trials. All marginal mandibular nerve injuries reported from the trials resolved without additional treatment (range 1-298 days, median 44 days).
To avoid the potential for marginal mandibular nerve injury, do not inject KYBELLA into or in close proximity to the marginal mandibular branch of the facial nerve .
Difficulty swallowing (dysphagia) occurred in KYBELLA-treated patients in clinical trials in the setting of administration site reactions, e.g., pain, swelling, and induration of the submental area. Cases of dysphagia resolved without additional treatment (range 1-81 days, median 3 days). Subjects with current or prior history of dysphagia were excluded from clinical trials.
Avoid use of KYBELLA in patients with a current or prior history of dysphagia because KYBELLA use may exacerbate the condition.
Injection Site Hematoma or Bruising
In clinical trials, 72% of subjects treated with KYBELLA had an injection site hematoma or bruising .
Use KYBELLA with caution in patients with bleeding abnormalities (e.g., taking antiplatelet or anticoagulant therapy) as excessive bleeding or bruising in the treatment area may occur.
Injection Site Alopecia
Cases of injection site alopecia have been reported with KYBELLA administration. The onset and duration of this adverse reaction may vary among individuals and may persist.
Consider withholding subsequent KYBELLA treatments until resolution of this adverse reaction.
Injection Site Ulceration, Necrosis, Nodule, Mass, and Infection
Very superficial injections (into the dermis) of KYBELLA may result in skin ulceration and necrosis . …
Deoxycholic Acid side effects
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In two double-blind, placebo-controlled clinical trials 513 subjects were treated with KYBELLA and 506 subjects were treated with placebo .
Subjects received up to 6 treatments at least 1 month apart and were followed for up to 6 months after the last received treatment.
The most commonly reported adverse reactions are listed below (Table 1).
Adverse reactions | KYBELLA
(N=513)
n (%) | Placebo
(N=506)
n
(%)
Injection site reactions | 492 (96%) | 411 (81%)
edema/swelling | 448 (87%) | 218 (43%)
hematoma/bruising | 368 (72%) | 353 (70%)
pain | 356 (70%) | 160 (32%)
numbness | 341 (66%) | 29 (6%)
erythema | 136 (27%) | 91 (18%)
induration | 120 (23%) | 13 (3%)
paresthesia | 70 (14%) | 20 (4%)
nodule | 68 (13%) | 14 (3%)
pruritus | 64 (12%) | 30 (6%)
skin tightness | 24 (5%) | 6 (1%)
site warmth | 22 (4%) | 8 (2%)
nerve injury b | 20 (4 %) | 1 (<1%)
Headache | 41 (8%) | 20 (4%)
Oropharyngeal pain | 15 (3%) | 7 (1%)
Hypertension | 13 (3%) | 7 (1%)
Nausea | 12 (2%) | 3 (1%)
Dysphagia | 10 (2%) | 1 (<1%)
a Adverse reactions that occurred in ≥ 2% KYBELLA treated subjects and at greater incidence than placebo
b Marginal mandibular nerve paresis
Other adverse reactions associated with the use of KYBELLA included injection …
About this medicine
The chemical name of deoxycholic acid is 3α,12α-dihydroxy-5β-cholan-24-oic acid, and its molecular formula is C24H40O4, and its molecular weight is 392.57 g/mol. The chemical structure of deoxycholic acid is:
KYBELLA (deoxycholic acid) injection, 10 mg/mL is a clear colorless, sterile solution for subcutaneous use. Each 2 mL vial of KYBELLA contains 20 mg of deoxycholic acid, a cytolytic agent, as the active ingredient and the following inactive ingredients: benzyl alcohol (18 mg), dibasic sodium phosphate (2.84 mg), sodium chloride (8.76 mg), sodium hydroxide (2.86 mg) in water for injection, USP. Hydrochloric acid and additional sodium hydroxide are added as necessary to adjust the formulation to pH 8.3. Each vial is for single patient use.
How it works: KYBELLA is a cytolytic drug, which when injected into submental fat - in patients with moderate to severe convexity or fullness associated with submental fat - physically destroys the cell membrane causing lysis. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID fe431ed4-ea6f-4e99-b4bc-ec25ae7b8553. Read the full official label on DailyMed.